跳至主要内容
临床试验/ACTRN12615001029583
ACTRN12615001029583已完成3 期

The use of exenatide, a GLP-1 agonist, in young people with cystic fibrosis related diabetes and impaired glucose tolerance in the management of post prandial glycaemia, gastric emptying and incretins.

Jennifer Couper0 个研究点目标入组 10 人开始时间: 2015年10月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
10 Years 至 25 Years(—)
性别
All

入选标准

  • Male or Female patients aged 10-25 years with cystic fibrosis with exocrine pancreatic insufficiency taking pancreatic enzymes.
  • Cystic Fibrosis Related Diabetes (CFRD) (2 hour glucose on routine OGTT >11.1 mmol/L),
  • OR CFRD without fasting hyperglycaemia,
  • OR Cystic Fibrosis with Impaired Glucose Tolerance (CF with IGT) (2 hour glucose >7.8mmol/L<11.1mmol/L)

排除标准

  • Severe pulmonary disease (FEV1 <30% predicted)
  • Significant liver disease (Child-Pugh score >6)
  • Requirement for medications that could affect gastrointestinal motility (eg. erythromycin, SSRI)
  • Severe renal impairment
  • Previous stomach or small bowel surgery
  • Pregnancy or lactation

研究者

发起方
Jennifer Couper

相似试验